Gut-signaling peptide medicines: three very different uses
Why linaclotide, plecanatide, and teduglutide are all gut-related peptides but are not interchangeable treatments or evidence for general gut repair.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
The quick overview
Linaclotide and plecanatide act locally at intestinal guanylate cyclase-C receptors to treat defined constipation disorders. Teduglutide is a GLP-2 analog that promotes intestinal adaptation in short bowel syndrome with parenteral-support dependence.
All three are FDA-approved peptide medicines, yet their diagnoses, endpoints, populations, systemic exposure, and risks are fundamentally different.
Side-by-side comparison
| Peptide | Status | Evidence | Studied for |
|---|---|---|---|
| Linaclotide | FDA approved for specific uses | Strong human evidence for approved uses | IBS with constipation; Chronic idiopathic constipation; Pediatric functional constipation |
| Plecanatide | FDA approved for specific uses | Strong human evidence for approved uses | Chronic idiopathic constipation; IBS with constipation; Abdominal pain and bloating |
| Teduglutide | FDA approved for specific uses | Strong human evidence for approved uses | Short bowel syndrome; Intestinal absorption; Parenteral-support reduction |
Studied for
IBS with constipation · Chronic idiopathic constipation · Pediatric functional constipation
Studied for
Chronic idiopathic constipation · IBS with constipation · Abdominal pain and bloating
Studied for
Short bowel syndrome · Intestinal absorption · Parenteral-support reduction
Approved versus investigational
An FDA approval means the agency reviewed evidence for a specific product, population, and use. It does not validate other molecules in the same family or uses outside the label. “In Phase 3” still means investigational.
What researchers are studying
- IBS with constipation
- Chronic and functional constipation
- Short bowel syndrome and intestinal failure
- Bowel symptoms, absorption, and parenteral-support needs
Risks and reasons for caution
- An approval for constipation is not evidence for intestinal growth or short bowel syndrome.
- Teduglutide's growth-promoting biology carries polyp, neoplasia, obstruction, and fluid-related concerns not shared in the same way by local secretagogues.
- None of these approvals establishes general microbiome optimization, gut healing, detoxification, or recovery.
What remains uncertain
- Long-term head-to-head effectiveness of the constipation peptides
- Reliable predictors of response and adverse effects
- Very long-term neoplasia and intestinal-autonomy outcomes with teduglutide
Questions to ask a healthcare professional
1. What exact diagnosed condition and endpoint does the evidence cover?
2. Does the peptide act locally at the gut surface or promote intestinal growth?
3. Is the reader in the approved adult, pediatric, or intestinal-failure population?
4. What risks follow directly from the peptide's mechanism?
Plain-English takeaway
‘Gut peptide’ is far too broad to guide a health decision. These medicines prove three narrow clinical claims—not a shared ability to repair or optimize the digestive system.
References
- 1FDA prescribing information: Linzess
Age-specific constipation indications and dehydration warning.
- 2FDA prescribing information: Trulance
Adult constipation indications, boxed warning, and adverse reactions.
- 3FDA prescribing information: Gattex
Short bowel syndrome indication and growth-related safety boundaries.
- 4Randomized teduglutide short bowel trial
Patient-population and endpoint evidence distinct from constipation trials.